Impact of antibiotic MIC on infection outcome in patients with susceptible gram-negative bacteria: A systematic review and meta-analysis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4214-4222

  Falagas, Matthew E ^a,b,c   Tansarli, Giannoula S ^a   Rafailidis, Petros I ^a,b   Kapaskelis, Anastasios ^a   Vardakas, Konstantinos Z ^a,b  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; DRUG DOSE COMPARISON; DRUG TREATMENT FAILURE; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFECTION; HUMAN; MEDLINE; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TYPHOID FEVER;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT FAILURE;

EID: 84864386803     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00663-12     Document Type: Review

References (23)

1. Anthony KB, et al. 2008. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46:567-570. (Pubitemid 351263497)
2. Bercion R, et al. 2008. Acute bacterial meningitis at the 'Complexe Pediatrique'of Bangui, Central African Republic. J. Trop. Pediatr. 54:125-128. (Pubitemid 351517021)
3. Bhat SV, et al. 2007. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob. Agents Chemother. 51:4390-4395. (Pubitemid 350209894)
4. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial testing: twenty-first informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Crump JA, et al. 2008. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States Foodnet multicenter retrospective cohort study. Antimicrob. Agents Chemother. 52:1278-1284. (Pubitemid 351521988)
6. Dagan R, et al. 1997. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J. Infect. Dis. 176:1253-1259. (Pubitemid 27460991)
7. Defife R, Scheetz MH, Feinglass JM, Postelnick MJ, Scarsi KK. 2009. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob. Agents Chemother. 53:1074-1079.
8. Drusano GL, Lode H, Edwards JR. 2000. Meropenem: clinical response in relation to in vitro susceptibility. Clin. Microbiol. Infect. 6:185-194. (Pubitemid 34966051)
9. Falagas ME, Karageorgopoulos DE. 2010. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 375:248-251.
10. Falagas ME, Siempos II, Bliziotis IA, Panos GZ. 2006. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Mayo Clin. Proc. 81:1567-1574. (Pubitemid 44871900)
11. Goethaert K, et al. 2006. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin. Microbiol. Infect. 12:56-62. (Pubitemid 43372240)
12. Lo JY, et al. 2008. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob. Agents Chemother. 52:3564 -3567.
13. Lorente L, et al. 2009. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int. J. Antimicrob. Agents 33:464-468.
14. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. 2006. Meropenem by continuous versus intermittent infusion in ventilatorassociated pneumonia due to gram-negative bacilli. Ann. Pharmacother. 40:219-223. (Pubitemid 43269850)
15. Parry CM, et al. 2011. The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy. PLoS Negl. Trop. Dis. 5:e1163.
16. Paterson DL, et al. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extendedspectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212. (Pubitemid 32531482)
17. Qureshi ZA, et al. 2011. Risk factors and outcome of extended-spectrum beta-lactamase-producing Enterobacter cloacae bloodstream infections. Int. J. Antimicrob. Agents 37:26-32.
18. Rodriguez-Bano J, et al. 2008. Community infections caused by extended- spectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med. 168:1897-1902.
19. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. 2012. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin. Infect. Dis. 54:167-174.
20. Rodriguez-Bano J, Picon E, Navarro MD, Lopez-Cerero L, Pascual A. 2011. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum betalactamase-producing Escherichia coli. Clin. Microbiol. Infect. [Epub ahead of print.]. doi:10.1111/j.1469-0691.2011.03673.x.
21. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. 2012. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob. Agents Chemother. 56:2129-2131.
22. Tam VH, et al. 2008. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin. Infect. Dis. 46:862-867. (Pubitemid 351417187)
23. Yamagishi Y, et al. 2012. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa. J. Infect. Chemother. 18:127-129.